

Our Docket: 19491

1/15

WO 2005/004990

Fig. 1: Feed and drink intake in the observation period





<sup>\*</sup> p<0.05 vs. control

## Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC **SYNDROME**

Our Docket: 19491

2/15

WO 2005/004990

-7

\* p<0.05 vs. control

0

7

14

21

28

PCT/EP2004/007690


42

Day of treatment

49


35


Fig. 2: Body mass and blood glucose concentration in the observation period (7 days before the start of treatment and up to 42 days of treatment)



3/15

Fig. 3a: Concentration of NEFA (non-esterified fatty acids) and insulin before the start of treatment, after 3 weeks and after 6 weeks of treatment mean ± SD






<sup>°</sup> p<0.05 vs. day 0 °° p<0.01 vs. day 0


## Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME Our Docket: 19491

WO 2005/004990

4/15


Fig. 3b: Concentrations of total and HDL cholesterol before the start of treatment, after 3 weeks and after 6 weeks of treatment, mean ± SD






5/15


Fig. 3c: Concentrations of LDL cholesterol and triglycerides before the start of treatment, after 3 weeks and after 6 weeks of treatment





6/15

Fig. 3d: Concentrations of C-reactive protein before the start of treatment, after 3 weeks and after 6 weeks of treatment, mean ± SD




Our Docket: 19491

WO 2005/004990

PCT/EP2004/007690

7/15

Fig. 3e: Number of leucocytes in 6-week observation period



## Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME


Our Docket: 19491


WO 2005/004990

PCT/EP2004/007690

8/15

Fig. 4a: Blood glucose curve in the oGTT and glucose excess areas before the start of treatment







mean ± SD

9/15

PCT/EP2004/007690

Fig. 4b: Curve of the insulin concentrations in the oGTT and insulin excess areas before the start of treatment







mean ± SD

10/15


Fig. 5a: Blood glucose curve in the oGTT and glucose excess areas after 3 weeks of treatment






11/15

Fig. 5b: Curve of the insulin concentrations in the oGTT and insuline excess areas after 3 weeks of treatment







12/15

PCT/EP2004/007690

Fig. 6a: Blood glucose curve in the oGTT and glucose excess areas after 6 weeks of treatment





mean  $\pm$  SD \* p<0.05 vs. control \*\* p<0.01 vs. control


## Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME


Our Docket: 19491

13/15

WO 2005/004990

Fig. 6b: Curve of the insulin concentrations in the oGTT and insulin excess areas after 6 weeks of treatment







14/15

WO 2005/004990

PCT/EP2004/007690

Fig. 7: Diurnal glood glucose and lactate profile before the start of treatment







PCT/EP2004/007690

15/15

Fig. 8: Diurnal blood glucose and lactate profile after 6 weeks of treatment





<sup>\*\*</sup> p<0.01 vs. control